Lilly misses earnings estimates but raises full-year outlook
Indianapolis-based Eli Lilly and Co. saw revenue in the third quarter increase 18 percent over the same period of 2020, to $6.77 billion.
Eli Lilly and Co.
Articles
Lilly CEO says letting Medicare negotiate drug prices would bring research cuts
“A cut [in drug prices] like is being proposed would have about a 40% reduction in our U.S. revenues,” Lilly CEO David Ricks said in a television interview this week with Gerry Dick on Inside Indiana Business, a division of IBJ Media.
Lilly’s antibody treatment gets another shot
The drugmaker’s COVID-19 treatment is back on the market after a two-month suspension, but the question is whether Lilly can grab market share from now-dominant Regeneron Pharmaceuticals.
U.S. government buys $330M worth of COVID-19 antibody doses from Lilly
Eli Lilly’s therapy has been shown to be highly effective against the delta variant, which is now the dominant strain of the coronavirus in the United States.
Lawsuit accuses Lilly of favoring millennials over older job applicants
Two former job applicants, aged 55 and 49, filed a proposed class-action lawsuit in U.S. District Court in Indianapolis on Wednesday, accusing the Indianapolis-based drug maker of age discrimination.
An Olympic medalist promotes Lilly’s migraine medicine (with an asterisk)
Eli Lilly and Co. has produced at least two video commercials featuring Olympic swimmer Ryan Murphy promoting its migraine treatment, Emgality. But one of the ads contains a fleeting disclaimer: Murphy doesn’t take Emgality.
Eli Lilly to require all U.S. employees to be vaccinated
The mandate covers about 15,400 Lilly employees in numerous states and Puerto Rico, including about 11,000 in Indiana.
Eli Lilly’s quarterly earnings fall short of expectations
Eli Lilly and Co. turned in a profitable second quarter, but the results were shy of Wall Street analyst predictions. The drugmaker, however, saw revenue growth that topped Wall Street expectations.
After uproar over FDA’s handling of Biogen Alzheimer’s drug, Lilly presses on
Even as some drugmakers, including Indianapolis-based Eli Lilly and Co., are pushing to get experimental drugs approved, federal regulators are still dealing with a huge blowback over the controversial way they reviewed a new Alzheimer’s drug by rival Biogen.
Lilly signs deal with California biotech to develop treatments for Lou Gehrig’s disease
The collaboration could be worth as much as $694 million and potential royalties to Verge Genomics if the two companies hit development milestones.
Controversial OK of Alzheimer’s drug reignites battle over disease’s cause
The role of the sticky substance in the brain has long divided researchers and is at the forefront again amid the FDA’s recent clearance of the first drug to treat the disease in almost two decades.
Lilly and former lobbyist resolve sex discrimination suit
In her complaint, the lobbyist had claimed a top executive made sexist comments about her, mocked her physical appearance and subjected her and other women to a hostile work environment.
UPDATE: Lilly to seek FDA approval for potential Alzheimer’s drug
Eli Lilly and Co. shares jumped more than 9% Thursday morning after it received “breakthrough therapy” designation for donanemab from the U.S. Food and Drug Administration, putting the drug on a path that could expedite its development.
2021 Indiana 100: Taltz leader sees more potential for blockbuster Lilly drug
Mathilde Merlet oversees one of Eli Lilly and Co.’s fastest-growing products, a medicine called Taltz that treats a variety of dermatology and rheumatology disorders.
Lilly’s COVID therapy hits wall as virus wanes
The use of COVID antibodies has fallen across the United States lately and, along with it, Lilly’s sales in that category.
Lilly’s stock gets big boost from competitor’s new Alzheimer’s treatment
Shares of Biogen competitors soared after aducanumab became the first drug cleared by the U.S. Food and Drug Administration to slow the course of the mind-wasting disease that afflicts 6 million Americans.
2021 Innovation Issue: Lilly’s disruptive model opens doors to women, minorities
For more than a century, Eli Lilly and Co. has pushed for innovation in the pharmaceutical industry. But six years ago, the drugmaker had to admit it was less than innovative in its own workforce.
Feds launch investigation of Lilly factory in New Jersey
Eli Lilly on Thursday said in a government filing that it has received a subpoena from the U.S. Justice Department for documents related to the factory and is cooperating with the investigation.
Lilly shares fall in pre-market trading after drugmaker’s profit dips
Shares of Eli Lilly and Co. dropped as much as 5% Tuesday morning after the Indianapolis-based drugmaker lowered guidance for full-year earnings.
Eli Lilly: Antibody combo works best on COVID-19 variants
The Indianapolis-based company is asking U.S. regulators to revoke their emergency authorization for the use of bamlanivimab alone, in favor of its combination with another drug.